SYN-Tech Chem & Pharm Co Ltd (1777) - Total Liabilities
Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) has total liabilities worth NT$369.57 Million TWD (≈ $11.64 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SYN-Tech Chem & Pharm Co Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of SYN-Tech Chem & Pharm Co Ltd to evaluate short-term liquidity relative to the company's equity base.
SYN-Tech Chem & Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of SYN-Tech Chem & Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MNtech Co. Ltd
KQ:095500
|
Korea | ₩317.45 Billion |
|
Hankook Cosmetics Manufacturing Co Ltd
KO:003350
|
Korea | ₩94.05 Billion |
|
Hammond Manufacturing Company Limited
TO:HMM-A
|
Canada | CA$108.77 Million |
|
Hyundai Everdigm Corp
KQ:041440
|
Korea | ₩127.88 Billion |
|
Eolus Vind AB (publ)
ST:EOLU-B
|
Sweden | Skr983.00 Million |
|
Fortune Oriental Co Ltd
TW:2491
|
Taiwan | NT$347.60 Million |
|
Bulten AB
ST:BULTEN
|
Sweden | Skr2.68 Billion |
|
Kootenay Silver Inc
V:KTN
|
Canada | CA$361.85K |
Liability Composition Analysis (2015–2025)
This chart breaks down SYN-Tech Chem & Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SYN-Tech Chem & Pharm Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SYN-Tech Chem & Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SYN-Tech Chem & Pharm Co Ltd (2015–2025)
The table below shows the annual total liabilities of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$369.57 Million ≈ $11.64 Million |
+26.72% |
| 2024-12-31 | NT$291.65 Million ≈ $9.19 Million |
-50.02% |
| 2023-12-31 | NT$583.48 Million ≈ $18.38 Million |
+0.58% |
| 2022-12-31 | NT$580.13 Million ≈ $18.28 Million |
-36.37% |
| 2021-12-31 | NT$911.71 Million ≈ $28.72 Million |
+68.38% |
| 2020-12-31 | NT$541.46 Million ≈ $17.06 Million |
-22.75% |
| 2019-12-31 | NT$700.89 Million ≈ $22.08 Million |
-3.44% |
| 2018-12-31 | NT$725.85 Million ≈ $22.87 Million |
+29.70% |
| 2017-12-31 | NT$559.62 Million ≈ $17.63 Million |
+115.30% |
| 2016-12-31 | NT$259.92 Million ≈ $8.19 Million |
+1.88% |
| 2015-12-31 | NT$255.12 Million ≈ $8.04 Million |
-- |
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more